Sixty-seven oncology physician group practices in 37 states will participate in the Enhanced Oncology Model, a voluntary five-year payment model that will begin July 1 for beneficiaries who receive systemic chemotherapy, the Centers for Medicare & Medicaid Services announced yesterday. The Center for Medicare and Medicaid Innovation model supports the administration’s moonshot goal to reduce cancer death rates by 50% over the next 25 years. Participating practices must provide 24/7 access to care, patient navigation and care planning; use certified electronic health record technology, evidence-based guidelines, electronic patient reported outcomes and data to improve quality; and must also screen for health-related social needs. The model will qualify as an alternative payment model under the Quality Payment Program’s Merit-based Incentive Payment System beginning in July. It offers two levels of downside risk, with the higher risk arrangement excluded from MIPS reporting requirements and payment adjustments as an Advanced APM. For more, see the model’s updated fact sheet.

Related News Articles

Headline
The AHA commented to the Centers for Medicare & Medicaid Services June 10 on the fiscal year 2026 inpatient prospective payment system proposed rule (https…
Headline
The AHA expressed concerns (LINK) to the Centers for Medicare & Medicaid Services today on payment updates for the fiscal year 2026 proposed rule for the…
Headline
The AHA commented on proposed changes to the Transforming Episode Accountability Model, a new, mandatory, episode-based payment model scheduled to begin Jan. 1…
Headline
The AHA June 10 commented on the fiscal year 2026 inpatient psychiatric facility proposed rule, expressing support for several provisions such as increases in…
Headline
The White House June 6 issued a memorandum directing the Secretary of the Department of Health and Human Services “to take appropriate action to eliminate…
Headline
The AHA June 4 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law…